TY - GEN
T1 - Multimodal classification of Dementia using functional data, anatomical features and 3D invariant shape descriptors
AU - Mikhno, Arthur
AU - Nuevo, Pablo Martinez
AU - Devanand, Davangere P.
AU - Parsey, Ramin V.
AU - Laine, Andrew F.
PY - 2012
Y1 - 2012
N2 - Multimodality classification of Alzheimer's disease (AD) and its prodromal stage, Mild Cognitive Impairment (MCI), is of interest to the medical community. We improve on prior classification frameworks by incorporating multiple features from MRI and PET data obtained with multiple radioligands, fluorodeoxyglucose (FDG) and Pittsburg compound B (PIB). We also introduce a new MRI feature, invariant shape descriptors based on 3D Zernike moments applied to the hippocampus region. Classification performance is evaluated on data from 17 healthy controls (CTR), 22 MCI, and 17 AD subjects. Zernike significantly outperforms volume, accuracy (Zernike to volume): CTR/AD (90.7% to 71.6%), CTR/MCI (76.2% to 60.0%), MCI/AD (84.3% to 65.5%). Zernike also provides comparable and complementary performance to PET. Optimal accuracy is achieved when Zernike and PET features are combined (accuracy, specificity, sensitivity), CTR/AD (98.8%, 99.5%, 98.1%), CTR/MCI (84.3%, 82.9%, 85.9%) and MCI/AD (93.3%, 93.6%, 93.3%).
AB - Multimodality classification of Alzheimer's disease (AD) and its prodromal stage, Mild Cognitive Impairment (MCI), is of interest to the medical community. We improve on prior classification frameworks by incorporating multiple features from MRI and PET data obtained with multiple radioligands, fluorodeoxyglucose (FDG) and Pittsburg compound B (PIB). We also introduce a new MRI feature, invariant shape descriptors based on 3D Zernike moments applied to the hippocampus region. Classification performance is evaluated on data from 17 healthy controls (CTR), 22 MCI, and 17 AD subjects. Zernike significantly outperforms volume, accuracy (Zernike to volume): CTR/AD (90.7% to 71.6%), CTR/MCI (76.2% to 60.0%), MCI/AD (84.3% to 65.5%). Zernike also provides comparable and complementary performance to PET. Optimal accuracy is achieved when Zernike and PET features are combined (accuracy, specificity, sensitivity), CTR/AD (98.8%, 99.5%, 98.1%), CTR/MCI (84.3%, 82.9%, 85.9%) and MCI/AD (93.3%, 93.6%, 93.3%).
KW - Alzheimer's
KW - multimodal
KW - PET
KW - SVM
KW - Zernike
UR - https://www.scopus.com/pages/publications/84864851328
U2 - 10.1109/ISBI.2012.6235621
DO - 10.1109/ISBI.2012.6235621
M3 - Conference contribution
AN - SCOPUS:84864851328
SN - 9781457718588
T3 - Proceedings - International Symposium on Biomedical Imaging
SP - 606
EP - 609
BT - 2012 9th IEEE International Symposium on Biomedical Imaging
T2 - 2012 9th IEEE International Symposium on Biomedical Imaging: From Nano to Macro, ISBI 2012
Y2 - 2 May 2012 through 5 May 2012
ER -